Researchers developed a new typing model that can better predict survival of diffuse large B-cell lymphoma (DLBCL) following chemotherapy. The findings were published in BMC Cancer.
In this study, researchers used B-cell receptor (BCR) repertoire sequencing and whole-exome sequencing to assess formalin-fixed paraffin-embedded samples from 12 patients with DLBCL who were divided into two clusters (cluster 1 and cluster 2). Subsequently, they developed a typing model with cluster analysis and prognostic indicators. They conducted mutation and bioinformatics analyses to discern any potential prognostic biomarkers within the patient sample.
The progression-free survival (PFS), overall survival (OS), metastasis, and Shannon diversity index of IGH V-J and survival after chemotherapy were significantly different between the two clusters, but no statistically significance difference was found between the GCB and non-GCB groups, the researchers noted. The results showed that the mutation status of 248 genes were notably different between the two clusters. Among them, the study identified some key genes, FTSJ3, MAGED2, and ODF3L2, which were the specific mutated genes in all patients in cluster 2.
“We constructed a new typing model of DLBCL based on BCR repertoire sequencing that can better predict the survival time after chemotherapy. FTSJ3, MAGED2, and ODF3L2 may represent key genes for the difference in prognosis between the two clusters,” the researchers concluded.